R&D Trends

Eli Lilly inks deals with Innovent Biologics, Hanmi Pharmaceutical

Friday, March 20, 2015 02:20 PM

Eli Lilly and Innovent Biologics, a biopharmaceutical company in China, have inked a biotech drug development collaboration to collaborate to support the development and potential commercialization of at least three cancer treatments over the next decade. The agreement creates possible new treatment options for cancer patients, while strengthening the presence of both companies in the Chinese oncology market.

More... »


Evotec, Sanofi ink agreement for multi-component alliance

Friday, March 20, 2015 02:19 PM

Evotec, a drug discovery alliance and development partnership company based in Germany, has signed an agreement for a major multi-component strategic alliance over the next five years with Sanofi. The transaction is expected to close March 31.

More... »


Daiichi Sankyo opens collaborative research and grants program

Friday, March 20, 2015 02:18 PM

Daiichi Sankyo, a global pharmaceutical company based in Japan, has announced its TaNeDS (Take a New challenge for Drug diScovery) collaborative drug discovery project for 2015. The company will select research partners for the project from researchers based in Japan. TaNeDS was launched in 2011 and has since received numerous research theme proposals from across Japan, with various projects currently ongoing.

More... »

AbbVie, C2N ink agreement for Alzheimer's disease therapy

Friday, March 20, 2015 02:06 PM

AbbVie has entered into an exclusive worldwide license agreement with C2N Diagnostics, a privately held protein diagnostic and therapeutic discovery company based in Saint Louis, Mo., to develop and commercialize a portfolio of anti-tau antibodies for the treatment of Alzheimer's disease and other neurological disorders. This partnership builds upon AbbVie's commitment to pursue transformational disease-modifying therapies in Alzheimer's disease.

More... »

Broad Institute, Calico collaborate on aging

Friday, March 20, 2015 01:56 PM

The Broad Institute of MIT and Harvard has entered into a partnership with Calico around the biology and genetics of aging and early-stage drug discovery. The partnership will support several efforts at the Broad Institute to advance the understanding of age-related diseases and to propel the translation of these findings into new therapeutics.

More... »

PTC Therapeutics, University of Pennsylvania collaborate on orphan disease research

Thursday, March 19, 2015 12:09 PM

PTC Therapeutics, a global biopharmaceutical company, has inked a collaboration with the Orphan Disease Center at the Perelman School of Medicine at the University of Pennsylvania focused on translational research for discovering and developing new treatments for orphan disorders. The partnership reflects both parties' commitment to developing treatments and improving the lives of those who suffer from rare diseases.

More... »

Tute Genomics, Google Genomics collaborate on genetic database

Thursday, March 19, 2015 12:03 PM

Tute Genomics, a Utah­-based provider of a clinical genome interpretation platform, along with Dr. Xiaoming Liu and his team at the University of Texas, have teamed up with Google to grant public access to a database of 8.5 billion annotations of genetic variants through Google Genomics.

More... »

Qiagen, Tokai Pharmaceuticals partner

Wednesday, March 18, 2015 01:18 PM

Qiagen, a Netherlands-based holding company, has partnered with Germany-based Tokai Pharmaceuticals to combine new circulating tumor cells (CTCs) technology with a molecular assay to co-develop and commercialize a companion diagnostic for Tokai's novel drug compound galeterone, which is in late-stage clinical trials for treatment of castration-resistant prostate cancer (CRPC). The non-invasive test will determine the expression of the AR-V7 biomarker, which in recent studies demonstrated potential utility to guide therapy choice in CRPC patients.

More... »

NantWorks, Sorrento collaborate on novel anti-cancer immunotherapies

Wednesday, March 18, 2015 01:16 PM

NantWorks, an umbrella organization developing of next generation diagnostics and therapeutics, and Sorrento Therapeutics, an oncology company, have entered into a binding agreement to initiate a global collaboration to discover and develop novel anti-cancer immunotherapies derived from Sorrento's proprietary G-MAB library against neoepitopes of tumor-specific antigens discovered using NantWorks' proprietary pan-omics based, precision medicine approach.

More... »

$100M invested in new Dementia Discovery fund

Wednesday, March 18, 2015 01:11 PM

The U.K. government has announced over $100 million will be invested in a pioneering new global Dementia Discovery Fund. Major pharmaceutical companies Biogen Idec, GlaxoSmithKline, Johnson & JohnsonEli Lilly and Pfizer have all committed in principle to investing in the project, alongside Alzheimer's Research U.K. and the U.K. government.

More... »

CenterWatch
CWWeekly

May 18

Research for All Act reaches Congress for second time seeking gender equality in basic research, clinical trials

MediciGlobal finds fewer trial dropouts among participants who actively pursue enrollment versus those recruited

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

May

Job satisfaction mixed as workload increases
Salaries not keeping pace with rise in work, responsibilities

Gamification moving from early science to patient use
Pharma looking to use games for early diagnosis, recruitment, adherence

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs